• Work With Us
    • Partnerships
      • We offer tailored partnerships to support and transform drug discovery.

        Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

    • Services
      • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

        As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

    • OrganoReady®
      • Our OrganoReady program is made for you when you need defined assays in ADME.

        We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Therapeutic Areas
  • Resources & Support
    • Knowledge Center
      • Get inspired by peer-reviewed publications, webinars, whitepapers, app notes and more in our knowledge center.

    • Blogs
      • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
    • Case Studies
      • Get inspired by research done by our scientists, partners, and customers around the globe.

    • Webinars & Events
    • Applications
  • About MIMETAS
  • News
  • We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need defined assays in ADME.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Get inspired by peer-reviewed publications, webinars, whitepapers, app notes and more in our knowledge center.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

MIMETAS participates in €325 million Oncode Accelerator initiative to accelerate and improve oncology drug development

LEIDEN, The Netherlands, April 14, 2022 - MIMETAS, a global leader in organ-on-chip-based disease models, is a partner in the Oncode Accelerator initiative that has been granted today an amount of €325 million by the Dutch National Growth Fund.

Oncode Institute will lead the Oncode Accelerator consortium and its operations. With this investment, the consortium will develop cancer drug candidates faster and bring them to patients sooner. As a partner in Oncode Accelerator, MIMETAS will develop the next generation of patient-specific cancer organoid models that include immune cells, blood vessels, and other essential cell types to drive novel cancer drug discovery and development. Using these models, MIMETAS will screen compounds and targets using fully integrated, automatic phenotypic screening lines with AI data interpretation, bringing early validation and de-risking to the cancer drug development pipeline.

“Drug pipeline efficiency and scarcity of novel targets and disease mechanisms are critical challenges for cancer drug discovery and the pharmaceutical industry,” says Jos Joore, co-CEO of MIMETAS, “We are excited to deploy our groundbreaking 3D human cancer models in this outstanding consortium to, ultimately, offer cancer patients a better future.”

The goal of Oncode Accelerator is to create a state-of-the-art drug development infrastructure to innovate the cancer drug development process itself. The project capitalizes on excellent cancer research in The Netherlands, one of the top three best-performing countries in biomedical sciences. In addition to MIMETAS, over forty leading parties from the oncology ecosystem participate in the consortium, including the Oncode Institute, pharmaceutical companies, SMEs, universities, hospitals, and social partners.

 

Read the full press release Sign up for our Newsletter

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all